Search

Your search keyword '"Blank, Christian"' showing total 1,201 results

Search Constraints

Start Over You searched for: Author "Blank, Christian" Remove constraint Author: "Blank, Christian"
1,201 results on '"Blank, Christian"'

Search Results

3. Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells

4. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

5. Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma

6. Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

7. Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance

10. PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial

11. Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021

12. The side effect registry immuno-oncology (SERIO) – A tool for systematic analysis of immunotherapy-induced side effects

14. The features and management of acquired resistance to PD1-based therapy in metastatic melanoma

15. Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response

16. Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study

17. Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

18. Neoadjuvant immunotherapy for melanoma is now ready for clinical practice

19. Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma

20. Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome

21. Response to checkpoint inhibition and targeted therapy in melanoma patients with concurrent haematological malignancies

23. B cells and tertiary lymphoid structures promote immunotherapy response

24. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials

25. Population mortality in advanced melanoma patients with and without response and progression; data from the Dutch Melanoma Treatment Registry

27. Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.

28. Quality of life with neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) versus adjuvant nivolumab in resectable stage III melanoma: 36-week data from the phase 3 NADINA trial.

29. The MARIANE-trial: Multicenter phase 1b/2 trial testing safety and efficacy of neoadjuvant intradermal ipilimumab and nivolumab in high-risk stage II melanoma.

30. A proof-of-concept study of sequential treatment with the HDAC inhibitor vorinostat following BRAF and MEK inhibitors in BRAFV600mutated melanoma

31. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial

32. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC)

33. Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study

34. Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd – 4th, 2021, Italy)

36. ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?

38. Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors

39. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial

40. A prediction model for response to immune checkpoint inhibition in advanced melanoma

41. BRAF/MEK inhibitor rechallenge in advanced melanoma patients

42. Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series

43. An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer

45. Temporal Dynamics of MOG Antibodies in Children With Acquired Demyelinating Syndrome

46. End-of-Life Use of Systemic Therapy in Patients With Advanced Melanoma: A Nationwide Cohort Study

47. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

48. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

49. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

50. Adjuvant treatment with anti‐PD‐1 in acral melanoma: A nationwide study.

Catalog

Books, media, physical & digital resources